ALK阳性晚期非小细胞肺癌治疗进展.pptVIP

ALK阳性晚期NSCLC治疗进展 NP-ALE-2017.10-004ValidUntil2019.10

ALK阳性晚期NSCLC治疗进展 ALK阳性NSCLC治疗现状ALK阳性NSCLC一线治疗的突破ALK阳性患者整体治疗策略

2016ALK+可见于约5%左右的晚期NSCLC病人每年新确诊75,000以上例患者ALK通路及药物发展简史2011Crizotinib,thefirstALKinhibitor,approved

2014(Jul)AlectinibapprovedinJapan2013(Jun)FDAgrantedAlectinibBTDforALK+NSCLCpatientswhohaveprogressedoncrizotinib2007JapaneseresearchersidentifiedALKoncogeneinNSCLCpatients2015(Dec)AlectinibFDAapprovalforALK-positiveNSCLCprogressingon/orintoleranttocrizitinib2016(Sep)FDAgrantedAlecensa2ndBTDfor1LALK+NSCLC2017(Feb)Alectini